Julien Ablain
Overview
Explore the profile of Julien Ablain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diazzi S, Ablain J
Trends Cancer
. 2023 Dec;
10(4):356-368.
PMID: 38135572
Epithelial cancers have served as a paradigm to study tumor dissemination but recent data have highlighted significant differences with nonepithelial cancers. Here, we review the current knowledge on nonepithelial tumor...
2.
Noureddine L, Ablain J, Surmieliova-Garnes A, Jacquemetton J, Pham T, Marangoni E, et al.
Life Sci Alliance
. 2023 Aug;
6(10).
PMID: 37536978
Triple-negative breast cancers (TNBCs) are the most aggressive breast cancers, and therapeutic options mainly rely on chemotherapy and immunotherapy. Although synthetic glucocorticoids (GCs) are given to alleviate the side effects...
3.
Ablain J, Al Mahi A, Rothschild H, Prasad M, Aires S, Yang S, et al.
Nat Genet
. 2022 Oct;
54(12):1839-1852.
PMID: 36229674
Cancer genetics has uncovered many tumor-suppressor and oncogenic pathways, but few alterations have revealed mechanisms involved in tumor spreading. Here, we examined the role of the third most significant chromosomal...
4.
Al Mahi A, Ablain J
Dis Model Mech
. 2022 Mar;
15(2).
PMID: 35234863
Activating mutations in RAS genes are the most common genetic driver of human cancers. Yet, drugging this small GTPase has proven extremely challenging and therapeutic strategies targeting these recurrent alterations...
5.
Fazio M, van Rooijen E, Dang M, van de Hoek G, Ablain J, Mito J, et al.
Elife
. 2021 Feb;
10.
PMID: 33527896
Recent genomic and scRNA-seq analyses of melanoma demonstrated a lack of recurrent genetic drivers of metastasis, while identifying common transcriptional states correlating with invasion or drug resistance. To test whether...
6.
Ablain J, Liu S, Moriceau G, Lo R, Zon L
J Exp Med
. 2020 Dec;
218(3).
PMID: 33306107
Functional evaluation of genetic lesions can discover a role in cancer initiation and progression and help develop novel therapeutic strategies. We previously identified the negative MAPK regulator SPRED1 as a...
7.
Choi J, Zhang T, Vu A, Ablain J, Makowski M, Colli L, et al.
Nat Commun
. 2020 Jun;
11(1):2718.
PMID: 32483191
Genome-wide association studies (GWAS) have identified ~20 melanoma susceptibility loci, most of which are not functionally characterized. Here we report an approach integrating massively-parallel reporter assays (MPRA) with cell-type-specific epigenome...
8.
Fazio M, Ablain J, Chuan Y, Langenau D, Zon L
Nat Rev Cancer
. 2020 Apr;
20(5):263-273.
PMID: 32251397
In precision oncology, two major strategies are being pursued for predicting clinically relevant tumour behaviours, such as treatment response and emergence of drug resistance: inference based on genomic, transcriptomic, epigenomic...
9.
Ablain J, Xu M, Rothschild H, Jordan R, Mito J, Daniels B, et al.
Science
. 2018 Nov;
362(6418):1055-1060.
PMID: 30385465
Melanomas originating from mucosal surfaces have low mutation burden, genomic instability, and poor prognosis. To identify potential driver genes, we sequenced hundreds of cancer-related genes in 43 human mucosal melanomas,...
10.
Yien Y, Shi J, Chen C, Cheung J, Grillo A, Shrestha R, et al.
J Biol Chem
. 2018 Oct;
293(51):19797-19811.
PMID: 30366982
Erythropoietin (EPO) signaling is critical to many processes essential to terminal erythropoiesis. Despite the centrality of iron metabolism to erythropoiesis, the mechanisms by which EPO regulates iron status are not...